FDA updates opioid labeling to raise awareness about naloxone

The Food and Drug Administration yesterday required updated labeling for opioid pain medicine and medicine to treat opioid use disorder to recommend that prescribers discuss naloxone with patients and caregivers.

“Today’s action can help further raise awareness about this potentially life-saving treatment for individuals that may be at greater risk of an overdose and those in the community most likely to observe an overdose,” said FDA Commissioner Stephen Hahn, M.D.